Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Supernus Pharmaceuticals, Inc.”

68 pharma patents match "Supernus Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 68
Index total 30,257
Page 1 / 3

Quick answer

This filtered view shows 68 pharmaceutical patents matching "Supernus Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

68 results for “Supernus Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 12121523

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted

  2. US 11911368

    Method of treatment of CNS disorders

    Supernus Pharmaceuticals, Inc. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted

  3. US 11896599

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted

  4. US 11638708

    Method of treatment of aggression

    Supernus Pharmaceuticals, Inc. · Granted May 2, 2023 · Expires Apr 27, 2043

    granted

  5. US 11458143

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted

  6. US 11351120

    Use of higher doses of modified release huperzine formulations

    Supernus Pharmaceuticals, Inc. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted

  7. US 11324753

    Method of treatment of attention deficit/hyperactivity disorder (ADHD)

    Supernus Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  8. US 11166960

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  9. US 11077114

    Stabilized formulations of CNS compounds

    Supernus Pharmaceuticals, Inc. · Granted Aug 3, 2021 · Expires Jul 29, 2041

    granted

  10. US 10314790

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  11. US 10265319

    Formulations of viloxazine

    Supernus Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  12. US 10220042

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  13. US 10201547

    Method of treatment of aggression

    Supernus Pharmaceuticals, Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted

  14. US 10160733

    Methods for producing viloxazine salts and novel polymorphs thereof

    Supernus Pharmaceuticals, Inc. · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted

  15. US 10149853

    Stabilized formulations of CNS compounds

    Supernus Pharmaceuticals, Inc. · Granted Dec 11, 2018 · Expires Dec 6, 2038

    granted

  16. US 10058556

    Method of treatment of aggression

    Supernus Pharmaceuticals, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted

  17. US 10005743

    Methods for producing viloxazine salts and novel polymorphs thereof

    Supernus Pharmaceuticals, Inc. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted

  18. US 9855278

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Jan 2, 2018 · Expires Dec 28, 2037

    granted

  19. US 9801887

    Method of treatment of aggression

    Supernus Pharmaceuticals, Inc. · Granted Oct 31, 2017 · Expires Oct 26, 2037

    granted

  20. US 9744137

    Topiramate compositions and methods of enhancing its bioavailability

    Supernus Pharmaceuticals, Inc. · Granted Aug 29, 2017 · Expires Aug 24, 2037

    granted

  21. US 9662338

    Formulations of viloxazine

    Supernus Pharmaceuticals, Inc. · Granted May 30, 2017 · Expires May 25, 2037

    granted

  22. US 9622983

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted

  23. US 9603853

    Formulations of viloxazine

    Supernus Pharmaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted

  24. US 9555004

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.